How to buy Abbott Laboratories (ABT) stocks

Abbott Laboratories is a medical devices business based in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $114.23 – an increase of 0.75% over the previous week. Abbott Laboratories employs 114,000 staff and has a trailing 12-month revenue of around $41.2 billion.

Our top picks for where to buy Abbott Laboratories stock

Buy Abbott Laboratories stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Abbott Laboratories stock price (NYSE: ABT)

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories stocks at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$114.23
52-week range	$99.24 - $121.00
50-day moving average more info button	$116.13
200-day moving average more info button	$110.77
Wall St. target price	$130.00
PE ratio more info button	34.0213
Dividend yield more info button	$2.2 (2.11%)
Earnings per share (TTM) more info button	$3.29

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Abbott Laboratories price performance over time

Historical closes compared with the close of $112.42 from 2024-12-19

1 week (2024-12-13)	-0.85%
1 month (2024-11-22)	-4.53%
3 months (2024-09-20)	-1.13%
6 months (2024-06-21)	6.34%

1 year (2023-12-22)	3.11%
2 years (2022-12-22)	8.27%
3 years (2021-12-22)	131.3871
5 years (2019-12-20)	41.55%

Is Abbott Laboratories stock undervalued or overvalued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Abbott Laboratories shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1998. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 billion.

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

Abbott Laboratories financials

Revenue TTM	$41.2 billion
Operating margin TTM	18.75%
Gross profit TTM	$24.6 billion
Return on assets TTM	6.49%
Return on equity TTM	14.84%
Profit margin	13.99%
Book value	$22.94
Market Capitalization more info button	$194.1 billion

TTM: trailing 12 months

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Abbott Laboratories was last rated for ESG on: 2019-01-01.

Total ESG score	32.35
Total ESG percentile	60.66
Environmental score	3.98
Environmental score percentile	5
Social score	20.71
Social score percentile	5
Governance score	13.15
Governance score percentile	5
Level of controversy	3

Abbott Laboratories stock dividends

Dividend payout ratio: 48.67% of net profits

Recently Abbott Laboratories has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.2 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 13 February 2025. The latest dividend was paid out to all shareholders who bought their stocks by 14 January 2025 (the "ex-dividend date").

Have Abbott Laboratories's stocks ever split?

Abbott Laboratories's stocks were split on a 10000:4798 basis on 1 January 2013 . So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories stocks – just the quantity. However, indirectly, the new 52% lower stock price could have impacted the market appetite for Abbott Laboratories stocks, which in turn could have impacted Abbott Laboratories's stock price.

Abbott Laboratories stock price volatility

Over the last 12 months, Abbott Laboratories's stocks have ranged in value from as little as $99.2377 up to $121. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.722. This would suggest that Abbott Laboratories's stocks are less volatile than average (for this exchange).

Abbott Laboratories overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois..

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Abbott Laboratories is owned by insiders or institutions?
Currently 0.531% of Abbott Laboratories stocks are held by insiders and 77.664% by institutions. How many people work for Abbott Laboratories?
Latest data suggests 114,000 work at Abbott Laboratories. When does the fiscal year end for Abbott Laboratories?
Abbott Laboratories's fiscal year ends in December. Where is Abbott Laboratories based?
Abbott Laboratories's address is: 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400 What is Abbott Laboratories's ISIN number?
Abbott Laboratories's international securities identification number is: US0028241000 What is Abbott Laboratories's CUSIP number?
Abbott Laboratories's Committee on Uniform Securities Identification Procedures number is: 002824126

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.